Skip to main content
Premium Trial:

Request an Annual Quote

Isis Sued by Tet Systems for Alleged Patent Infringement

Premium

Isis Pharmaceuticals this week was sued by Germany's Tet Systems for allegedly infringing two US patents related to controllable gene expression technology, according to court documents.

Tet's technology involves the use of tetracycline to turn on or off the expression of specific genes at specific times.

According to Tet's suit, Isis allegedly used a cell line, called HepAD38, that contains the entire hepatitis B virus genome under the control of tetracycline prior to the expiration of two patents covering the technology, namely US patent Nos. 5,464,758 and 6,914,124.

Isis did so without "a license or other consent," and included data derived from this use in two of its patent applications, Tet charged in its suit.

"Isis' infringement has been knowing and willful," Tet added.

The suit seeks a declaration of Isis' infringement and an undisclosed award of damages.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.